U.S. markets open in 2 hours 1 minute

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.20-0.06 (-0.49%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close12.26
Open12.39
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range11.94 - 12.83
52 Week Range1.48 - 14.62
Volume516,974
Avg. Volume1,126,216
Market Cap557.082M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-1.26
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.27
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
    Business Wire

    Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 p.m. ET Friday, February 26, 2021.

  • Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ownership Structure Tell Us Something Useful?

    A look at the shareholders of Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) can tell us which group is most powerful...

  • Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
    Business Wire

    Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design

    Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the finalization of the design of the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry eye chamber will be the primary endpoint. Approximately 150 dry eye disease patients are expected to be enrolled per arm. The TRANQUILITY protocol will utilize the two-day dosing paradigm, dry eye challenge design, and enrollment criteria of the run-in cohort.